These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18846054)

  • 1. Roche consolidates grip on anti-angiogenesis market.
    Moran N
    Nat Biotechnol; 2008 Oct; 26(10):1055-6. PubMed ID: 18846054
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent patent applications in angiogenesis research.
    Nat Biotechnol; 2006 Feb; 24(2):155. PubMed ID: 16465155
    [No Abstract]   [Full Text] [Related]  

  • 3. Recombinant protein therapeutics--success rates, market trends and values to 2010.
    Pavlou AK; Reichert JM
    Nat Biotechnol; 2004 Dec; 22(12):1513-9. PubMed ID: 15583654
    [No Abstract]   [Full Text] [Related]  

  • 4. Market watch: upcoming market catalysts in Q3 2012.
    Jeng R
    Nat Rev Drug Discov; 2012 Jun; 11(7):508. PubMed ID: 22743969
    [No Abstract]   [Full Text] [Related]  

  • 5. Fishing and frogging for anti-angiogenic drugs.
    De Smet F; Carmeliet P; Autiero M
    Nat Chem Biol; 2006 May; 2(5):228-9. PubMed ID: 16619017
    [No Abstract]   [Full Text] [Related]  

  • 6. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
    Roukos DH; Tzakos A; Zografos G
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
    [No Abstract]   [Full Text] [Related]  

  • 7. Market watch: Upcoming catalysts in Q3 2014.
    Haggerty R
    Nat Rev Drug Discov; 2014 Jul; 13(7):486. PubMed ID: 24981351
    [No Abstract]   [Full Text] [Related]  

  • 8. Written in the blood.
    Lewis R
    Nature; 2006 Mar; 440(7084):710-1. PubMed ID: 16637100
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharma consolidates its grip on post-antibody landscape.
    Sheridan C
    Nat Biotechnol; 2007 Apr; 25(4):365-6. PubMed ID: 17420728
    [No Abstract]   [Full Text] [Related]  

  • 10. The long and winding road.
    Nat Rev Drug Discov; 2005 Jun; 4(6):443. PubMed ID: 15959946
    [No Abstract]   [Full Text] [Related]  

  • 11. Market watch : Pharma industry strategic performance: 2007-2012E.
    Goodman M
    Nat Rev Drug Discov; 2008 Dec; 7(12):967. PubMed ID: 19043444
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer angiogenesis: targeting the heel of Achilles.
    Dass CR; Choong PF
    J Drug Target; 2008 Jul; 16(6):449-54. PubMed ID: 18604657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Companies eye slice of age-related macular degeneration market.
    Waltz E
    Nat Biotechnol; 2006 Sep; 24(9):1041-2. PubMed ID: 16964195
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anti-angiogenic therapy in ocular disease--current and future strategies].
    Agostini H; Feltgen N; Hansen L
    Klin Monbl Augenheilkd; 2008 Jan; 225(1):39-43. PubMed ID: 18236368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of angiogenesis: new hopes for oncologists, new challenges for anesthesiologists.
    Libert N; Tourtier JP; Védrine L; Chargari C
    Anesthesiology; 2010 Sep; 113(3):704-12. PubMed ID: 20693871
    [No Abstract]   [Full Text] [Related]  

  • 16. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 17. Tysabri back on market.
    Sheridan C
    Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
    [No Abstract]   [Full Text] [Related]  

  • 18. [Angiogenesis inhibitors and radiation therapy: concept and preliminary results].
    Mazeron R; Bourhis J; Deutsch E
    Bull Cancer; 2009 Mar; 96(3):299-310. PubMed ID: 19318308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Angiogenic inhibitors and radiotherapy: from the concept to the clinical trial].
    Cohen-Jonathan Moyal E
    Cancer Radiother; 2009 Oct; 13(6-7):562-7. PubMed ID: 19695923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization.
    Kelland L
    Curr Opin Mol Ther; 2007 Feb; 9(1):86-91. PubMed ID: 17330406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.